Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

American Journal of Psychiatry

Volumn 157, Issue 6, 2000, Pages 975-981

  Henderson, David C ^a   Cagliero, Enrico ^b   Gray, Colin ^b   Nasrallah, Rima A ^b   Hayden, Doug L ^b   Schoenfeld, David A ^b   Goff, Donald C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; VALPROIC ACID;

ADULT; AGE; AGED; ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; FEMALE; GLUCOSE TOLERANCE; HIGH RISK PATIENT; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOIDISM; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CLOZAPINE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; MALE; OBESITY; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; TRIGLYCERIDES; VALPROIC ACID;

EID: 0034042934     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.6.975     Document Type: Article

References (45)

1. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
2. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-897
3. Kane JM: Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry Suppl 1992; 17:41-45
4. Honigfeld G: The Clozapine National Registry system: forty years of risk management. J Clin Psychiatry Monograph 1996; 14:29-32
5. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozapine National Registry. J Clin Psychiatry 1998; 59(suppl 3):3-7
6. Glazer WM, Dickson RA: Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998; 59(suppl 3):8-14
7. Meltzer HY: Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998; 59(suppl 3):15-20
8. Harris EC, Barraclough B: Excess mortality of mental disorder. Br J Psychiatry 1998; 173:11-53
9. Walker AM, Lanza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677
10. Ghaeli P, Dufresne RL: Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079-2081
11. Umbricht DSG, Pollack S, Kane JM: Clozapine and weight gain. J Clin Psychiatry 1994; 55(Sept suppl B):157-160
12. Bustillo JR, Buchanan RW, Irish D, Breier A: Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153:817-819
13. Lamberti JS, Bellnier T, Schwarzkopf SB: Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149:689-690
14. Cohen S, Chiles J, MacNaughton A: Weight gain associated with clozapine. Am J Psychiatry 1990; 147:503-504
15. Koval MS, Rames LJ, Christie S: Diabetic ketoacidosis associated with clozapine treatment (letter). Am J Psychiatry 1994; 151: 1520-1521
16. Kostakoglu AE, Yazici KM, Erbas T, Guvener N: Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996; 93:217-218
17. Peterson GA, Byrd SL: Diabetic ketoacidosis from clozapine and lithium cotreatment (letter). Am J Psychiatry 1996; 153:737-738
18. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE: Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108-111
19. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44:778-783
20. Amdisen A: Drug-produced obesity: experiences with chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull 1964; 11:182-189
21. Leadbetter R, Shutty M, Pavalonis D, Viewig V, Higgins P, Downs M: Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149:68-72
22. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 1993; 119(7, part 2):655-660
23. Smith H, Kenney-Herbert J, Knowles L: Clozapine-induced diabetic ketoacidosis. Aust NZ J Psychiatry 1999; 33:121-122
24. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L: Severe hyperglycemia associated with high doses of clozapine (letter). Am J Psychiatr, 1994; 151:1395
25. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59:294-299
26. Mukherjee S, Decina P, Bocola V, Saracini F, Scapicchio PL: Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37:68-73
27. Kenny SJ, Aubert RE, Geiss LS: Prevalence and incidence of non-insulin-dependent diabetes, in Diabetes in America, 2nd ed: NIH Publication 95-1468. Bethesda, Md, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, pp 47-68
28. Keskiner A, el-Toumi A, Bousquet T: Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics 1973; 14: 176-181
29. Mukherjee S, Roth SD, Sandyk R, Shnur DB: Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 1989; 29:17-27
30. Schwartz L, Munoz R: Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 1968; 125:253-255
31. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN: Drug-induced disorders of glucose tolerance. Ann Intern Med 1993; 118:529-539
32. Bowes WA, Katta LR, Droegemeuller W, Bright TG: Triphasic randomized clinical trial: comparison of effects on carbohydrate metabolism. Am J Obstet Gynecol 1989; 161:1402-1407
33. Wynn V: Effects of duration of low-dose oral contraceptive administration on carbohydrate metabolism. Am J Obstet Gynecol 1982; 162:739-746
34. Thonnard-Neuman E: Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124:978-982
35. Proakis AG, Mennear JH, Miya TS, Borowitz JL: Phenothiazine-induced hyperglycemia: relation to CNS and adrenal effects. Proc Soc Exp Biol Med 1971; 137:1385-1388
36. Tollefson G, Lesar T: Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry 1983; 44:347-348
37. Isojarvi JIT, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS: Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-451
38. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383-1388
39. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-1057
40. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group: Technical Report 727. Geneva, WHO, 1985
41. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197
42. Zimmet PZ: Kelly West Lecture 1991: Challenges in diabetes epidemiology - from West to the rest. Diabetes Care 1992; 15: 232-252
43. Marshall JA, Shetterly S, Baxter J, Murmman RF: Dietary fat as a risk factor for conversion from impaired glucose tolerance (IGT) to non-insulin dependent diabetes mellitus (NIDDM): the San Luis Valley Diabetes Study (abstract). Diabetes 1990; 40(suppl 1):1500A
44. Feskens EJM, Krombout D: Habitual dietary intake and glucose intolerance in euglycaemic men: the Zutphen Study. Int J Epidemiol 1990; 19:953-959
45. Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, Muntwyler J, Luethy A, Gasser T, Follath F: Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994; 90:2230-2235